At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease, today announced that preclinical data...
Pulmatrix, Inc., (NASDAQ: PULM) will present at the Rodman & Renshaw 17th Annual Global Investment Conference on Thursday, September 10, 2015 at 11:40 am EDT. As part of the presentation, Robert...
Pulmatrix, Inc. (NASDAQ: PULM) has been granted U.S. patent 9,119,778, for the Company's underlying iSPERSE™ inhaled dry powder technology. The patent broadly covers small, dense and dispersible...
Pulmatrix, Inc., (NASDAQ: PULM) reports second quarter financial results and provides an update on the progress year to date on the business and its drug development pipeline. "During the second...
Pulmatrix, Inc., (NASDAQ: PULM) will webcast an investor presentation August 6, 2015 at 10:45 am EDT. As part of the presentation, Robert Clarke, Chief Executive Officer, will review Pulmatrix's...
Pulmatrix, Inc. (NASDAQ: PULM) has been granted two patents from the U.S. Patent and Trademark Office (U.S. Patent # 8,992,983 and U.S. patent # 9,061,352), which cover the composition of matter...
Dear Fellow Shareholders, The Pulmatrix management team and I would like to thank our founding institutional shareholders for their continued support and investment. Additionally, we want to...
Pulmatrix, Inc. (NASDAQ: PULM) announced today the appointment of William Duke, Jr., as chief financial officer. Mr. Duke previously served as chief financial officer of Valeritas, Inc., a company...
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced the appointment of Michael...
Pulmatrix (Nasdaq: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced that it has entered into an ex-U.S....